Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women

High-risk human papillomaviruses (HR-HPV) are the necessary cause of cervical carcinomas. To determine whether HPR-HPV DNA detection in primary routine screening could represent a sensitive and reliable technique for the detection of high-grade squamous intraepithelial lesions (HGSIL), laboratory analysis using 2 cytologic techniques (conventional and liquid-based), HPV testing with Hybrid Capture II assay (HC-II), followed by colposcopic examination of women with abnormal cervical finding and/or persistent HR-HPV infection, was conducted in 7932 women who had routine cervical examination. The sensitivity of HPV testing for detecting a histologically proven HGSIL was 100%, higher than that of conventional (68.1%) and liquid-based (87.8%) cytology. The low specificities of 85.6% and 87.3% of HPV testing slightly increased to 88.4% and 90.1% if HPV testing was reserved for woman >30 years old. The quantitative approach provided by the HC-II assay for the assessment of the viral load was not reliable for predicting HGSIL in normal smears. HR-HPV testing could be proposed in primary screening in association with cytology. With conventional cytology it significantly improves the detection of HGSIL. With the use of the same cervical scrape for HPV testing and liquid-based cytology, HR-HPV testing would allow to select positive samples treated in a second time for cytology which gives a good specificity. © 2001 Cancer Research Campaign http://www.bjcancer.com

[1]  K. Beutner Human papillomavirus infection. , 1989, Journal of the American Academy of Dermatology.

[2]  C. Peyton,et al.  Comparison of PCR- and Hybrid Capture-Based Human Papillomavirus Detection Systems Using Multiple Cervical Specimen Collection Strategies , 1998, Journal of Clinical Microbiology.

[3]  C. Clavel,et al.  Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions. , 1998, Journal of clinical pathology.

[4]  R Reid,et al.  Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. , 1992, Obstetrics and gynecology.

[5]  C. Clavel,et al.  Comparative analysis of human papillomavirus detection by hybrid capture assay and routine cytologic screening to detect high‐grade cervical lesions , 1998, International journal of cancer.

[6]  C. Meijer,et al.  PCR‐based high‐risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears , 1996, International journal of cancer.

[7]  A. Schneider,et al.  Screening for cervical intraepithelial neoplasia grade 2/3: validity of cytologic study, cervicography, and human papillomavirus detection. , 1996, American journal of obstetrics and gynecology.

[8]  H. zur Hausen Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. , 1994, Current topics in microbiology and immunology.

[9]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[10]  J. T. Cox,et al.  Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. , 1995, American journal of obstetrics and gynecology.

[11]  R. Hiatt,et al.  Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. , 1999, JAMA.

[12]  L. Koutsky,et al.  Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. , 2000 .

[13]  David R. Scott,et al.  A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. , 2001, The Journal of infectious diseases.

[14]  S Wacholder,et al.  HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. , 2000, JAMA.

[15]  J. Cuzick,et al.  Human papillomavirus testing in primary cervical screening , 1995, The Lancet.

[16]  R. Kaufman,et al.  Is human papillomavirus testing of value in clinical practice? , 1999, American journal of obstetrics and gynecology.

[17]  Julian Peto,et al.  Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .

[18]  C. Clavel,et al.  Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women , 1999, British Journal of Cancer.

[19]  L Beardsley,et al.  Natural history of cervicovaginal papillomavirus infection in young women. , 1998, The New England journal of medicine.

[20]  T. Rohan,et al.  Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. , 1999, The Journal of infectious diseases.

[21]  H. Adami,et al.  Natural history of cervical neoplasia: consistent results obtained by an identification technique. , 1989, British Journal of Cancer.

[22]  M. Plummer,et al.  Population-Based Study of Human Papillomavirus Infection and Cervical Neoplasia in Rural Costa Rica , 2000 .

[23]  T. Wright,et al.  Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. , 2000, Journal of the National Cancer Institute.

[24]  J. Cuzick,et al.  HPV testing in primary screening of older women , 1999, British Journal of Cancer.

[25]  R. Burk,et al.  Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. , 1995, Journal of the National Cancer Institute.

[26]  G. Rebello,et al.  Human papillomavirus testing , 2001, BMJ : British Medical Journal.

[27]  S. Vernon,et al.  Comparison of Human Papillomavirus Detection and Typing by Cycle Sequencing, Line Blotting, and Hybrid Capture , 2000, Journal of Clinical Microbiology.

[28]  J. Cuzick,et al.  A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions , 2000, British Journal of Cancer.

[29]  P. Arveux,et al.  Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction. , 1999 .

[30]  E. Franco,et al.  Human papillomavirus testing for primary screening of cervical cancer precursors. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[31]  T. Wright,et al.  Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. , 1998, American journal of obstetrics and gynecology.

[32]  J. Walboomers,et al.  Human papillomavirus DNA and genotypes: prognostic factors for progression of cervical intraepithelial neoplasia , 1993, International Journal of Gynecologic Cancer.

[33]  C. Meijer,et al.  The presence of persistent high‐risk hpv genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months , 1995, International journal of cancer.

[34]  Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. , 1995, American journal of obstetrics and gynecology.

[35]  Jacalyn L. Papillo,et al.  Evaluation of the ThinPrep Pap Test in Clinical Practice , 1998, Acta Cytologica.

[36]  J. Walboomers,et al.  HPV typing and testing in gynaecological pathology: has the time come? , 1998, Histopathology.

[37]  J. Cuzick,et al.  Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. , 1994, British Journal of Cancer.

[38]  Mark H Stoler,et al.  Advances in Cervical Screening Technology , 2000, Modern Pathology.

[39]  M. Plummer,et al.  Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. , 2000, Journal of the National Cancer Institute.

[40]  A. Lorincz Hybrid Capture™ Method for Detection of Human Papillomavirus DNA in Clinical Specimens: A Tool for Clinical Management of Equivocal Pap Smears and for Population Screening , 1996 .

[41]  M. Schiffman,et al.  Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. , 2001, Journal of the National Cancer Institute.

[42]  S. Crawford Screening for cervical intraepithelial neoplasia , 1994, BMJ.

[43]  A. Morabia,et al.  Efficacy of a liquid‐based thin layer method for cervical cancer screening in a population with a low incidence of cervical cancer , 2000 .

[44]  H. Adami,et al.  Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study , 2000, The Lancet.

[45]  A. Lörincz,et al.  Hybrid Capture™ Method for Detection of Human Papillomavirus DNA in Clinical Specimens: A Tool for Clinical Management of Equivocal Pap Smears and for Population Screening , 1996, The journal of obstetrics and gynaecology research.

[46]  R. Ashfaq,et al.  Performance of liquid-based, thin-layer cervical cytology: correlation with reference diagnoses and human papillomavirus testing. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[47]  W. Reeves,et al.  Is human papillomavirus testing an effective triage method for detection of high-grade (grade 2 or 3) cervical intraepithelial neoplasia? , 1998, American journal of obstetrics and gynecology.